{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:22:58Z","timestamp":1789597378055,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Regulatory Peptides"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.regpep.2003.11.003","type":"journal-article","created":{"date-parts":[[2004,1,17]],"date-time":"2004-01-17T05:15:06Z","timestamp":1074316506000},"page":"89-97","source":"Crossref","is-referenced-by-count":32,"title":["Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1"],"prefix":"10.1016","volume":"118","author":[{"given":"Michael A","family":"Nauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Walberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vethacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"El-Ouaghlidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Senkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Baptist Gallwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Schmiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.regpep.2003.11.003_BIB1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01225454","article-title":"The incretin concept today","volume":"16","author":"Creutzfeldt","year":"1979","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2003.11.003_BIB2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/dmr.5610080206","article-title":"Gut hormones and diabetes mellitus","volume":"8","author":"Creutzfeldt","year":"1992","journal-title":"Diabetes\/Metab. Rev."},{"key":"10.1016\/j.regpep.2003.11.003_BIB3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 [7\u201336]: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.regpep.2003.11.003_BIB4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/jc.76.4.912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7\u201336) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.regpep.2003.11.003_BIB5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diabetes.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans","volume":"43","author":"\u00d8rskov","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2003.11.003_BIB6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"\u00d8rskov","year":"1996","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.regpep.2003.11.003_BIB7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archinte.123.3.261","article-title":"Entero-insular axis","volume":"123","author":"Unger","year":"1969","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.regpep.2003.11.003_BIB8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.regpep.2003.11.003_BIB9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2003.11.003_BIB10","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.1152\/ajpendo.1988.254.3.E349","article-title":"Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans","volume":"254","author":"Tillil","year":"1988","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.regpep.2003.11.003_BIB11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.regpep.2003.11.003_BIB12","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1073\/pnas.96.26.14843","article-title":"Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice","volume":"96","author":"Miyawaki","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.regpep.2003.11.003_BIB13","first-page":"136","article-title":"Management of glucose abnormalities in patients receiving total parenteral nutrition","volume":"8","author":"Knapke","year":"1989","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.regpep.2003.11.003_BIB14","first-page":"481","article-title":"Aging exaggerates the blood glucose response to total parenteral nutrition","volume":"39","author":"Watters","year":"1996","journal-title":"Can. J. Surg."},{"key":"10.1016\/j.regpep.2003.11.003_BIB15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/011542659701200135","article-title":"Management of hyperglycemia in hospitalized patients receiving parenteral nutrition","volume":"12","author":"McMahon","year":"1997","journal-title":"Nutr. Clin. Prac."},{"key":"10.1016\/j.regpep.2003.11.003_BIB16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"10.1016\/j.regpep.2003.11.003_BIB17","first-page":"A215","article-title":"Reduction in hyperglycaemia by intravenous GLP-1 in patients under parenteral nutrition (abstract)","volume":"45","author":"Nauck","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2003.11.003_BIB18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jc.87.3.1239","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.regpep.2003.11.003_BIB19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/bj2070381","article-title":"Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33\u201369) of glicentin","volume":"207","author":"Holst","year":"1982","journal-title":"Biochem. J."},{"key":"10.1016\/j.regpep.2003.11.003_BIB20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diabetes.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2003.11.003_BIB21","first-page":"302","article-title":"Is GLP-1 (9\u201336)amide an endogenous antagonist at GLP-1 receptors? (abstract)","volume":"55","author":"Grandt","year":"1994","journal-title":"Digestion"},{"key":"10.1016\/j.regpep.2003.11.003_BIB22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2003.11.003_BIB23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s001250050664","article-title":"Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM","volume":"40","author":"Rachman","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2003.11.003_BIB24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa011300","article-title":"Intensive insulin therapy in the critically ill patients","volume":"345","author":"van den Berghe","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.regpep.2003.11.003_BIB25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00581038","article-title":"Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7\u201336 amide] in the fasting state in healthy subjects","volume":"32","author":"Qualmann","year":"1995","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.regpep.2003.11.003_BIB26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1464-5491.2001.00424.x","article-title":"No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose","volume":"18","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabet. Med."},{"key":"10.1016\/j.regpep.2003.11.003_BIB27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","article-title":"Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7\u201336 amide] after subcutaneous injection in healthy volunteers. Dose\u2013response-relationships","volume":"38","author":"Ritzel","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2003.11.003_BIB28","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s001250050613","article-title":"Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7\u201336 amide]) in patients with NIDDM","volume":"39","author":"Nauck","year":"1996","journal-title":"Diabetologia"}],"container-title":["Regulatory Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167011503002829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167011503002829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T09:30:19Z","timestamp":1550223019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167011503002829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":28,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0167011503002829"],"URL":"https:\/\/doi.org\/10.1016\/j.regpep.2003.11.003","relation":{},"ISSN":["0167-0115"],"issn-type":[{"value":"0167-0115","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}